📊 CYCN Key Takeaways
Investment Thesis
Cyclerion is a pre-revenue pharmaceutical company with severe operational losses and negative cash burn. With only $1.0M in revenue against $4.1M operating losses, the company is burning cash at an unsustainable rate with just $4.6M cash remaining and no clear path to profitability.
CYCN Strengths
- Strong liquidity position with 5.78x current ratio providing near-term survival runway
- Zero debt burden eliminates financial leverage risk
- Meaningful cash reserves of $4.6M relative to asset base
CYCN Risks
- Severe cash burn of $1.7M quarterly with operating losses of $4.1M indicates runway of less than 3 quarters without additional funding
- Revenue of $1.0M is negligible for a biopharmaceutical company, suggesting failed commercialization or non-existent product sales
- Negative operating margin of -394% and net margin of -260% indicate fundamental business model failure
- Zero insider transactions in 90 days suggests management confidence issues or restricted trading windows
- Pre-commercial or failed-commercial stage company with no visibility to positive cash flow
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway before capital raise necessity
- Revenue growth trajectory and clinical development milestones
- Operating expense reduction and path to cash flow breakeven
CYCN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.78x current ratio provides a solid financial cushion.
CYCN Profitability Ratios
CYCN vs Healthcare Sector
How Cyclerion Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CYCN Balance Sheet & Liquidity
CYCN 5-Year Financial Trend
5-Year Trend Summary: Cyclerion Therapeutics, Inc.'s revenue has declined by 56% over the 5-year period, indicating business contraction. The most recent EPS of $-2.25 indicates the company is currently unprofitable.
CYCN Growth Metrics (YoY)
CYCN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $194.0K | -$324.0K | $-0.29 |
| Q2 2025 | N/A | -$324.0K | $-0.11 |
| Q1 2025 | N/A | -$1.4M | $-0.56 |
| Q3 2024 | N/A | -$723.0K | $-0.29 |
| Q3 2023 | N/A | -$3.6M | $-1.55 |
| Q2 2023 | N/A | -$4.2M | $-1.83 |
| Q1 2023 | N/A | -$7.0M | $-0.16 |
| Q3 2022 | N/A | -$10.5M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CYCN Capital Allocation
CYCN SEC Filings
Access official SEC EDGAR filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYCN
What is the AI rating for CYCN?
Cyclerion Therapeutics, Inc. (CYCN) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYCN's key strengths?
Strong liquidity position with 5.78x current ratio providing near-term survival runway. Zero debt burden eliminates financial leverage risk.
What are the risks of investing in CYCN?
Severe cash burn of $1.7M quarterly with operating losses of $4.1M indicates runway of less than 3 quarters without additional funding. Revenue of $1.0M is negligible for a biopharmaceutical company, suggesting failed commercialization or non-existent product sales.
What is CYCN's revenue and growth?
Cyclerion Therapeutics, Inc. reported revenue of $1.0M.
Does CYCN pay dividends?
Cyclerion Therapeutics, Inc. does not currently pay dividends.
Where can I find CYCN SEC filings?
Official SEC filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYCN's EPS?
Cyclerion Therapeutics, Inc. has a diluted EPS of $-0.92.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.